These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37746083)

  • 21. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
    Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
    Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
    Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.
    Havers FP; Pham H; Taylor CA; Whitaker M; Patel K; Anglin O; Kambhampati AK; Milucky J; Zell E; Moline HL; Chai SJ; Kirley PD; Alden NB; Armistead I; Yousey-Hindes K; Meek J; Openo KP; Anderson EJ; Reeg L; Kohrman A; Lynfield R; Como-Sabetti K; Davis EM; Cline C; Muse A; Barney G; Bushey S; Felsen CB; Billing LM; Shiltz E; Sutton M; Abdullah N; Talbot HK; Schaffner W; Hill M; George A; Hall AJ; Bialek SR; Murthy NC; Murthy BP; McMorrow M
    JAMA Intern Med; 2022 Oct; 182(10):1071-1081. PubMed ID: 36074486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Influenza Vaccination With SARS-CoV-2 Infection and Associated Hospitalization and Mortality Among Patients Aged 66 Years or Older.
    Hosseini-Moghaddam SM; He S; Calzavara A; Campitelli MA; Kwong JC
    JAMA Netw Open; 2022 Sep; 5(9):e2233730. PubMed ID: 36169955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 Vaccination and Clinical Presentation of COVID-19 in Patients Hospitalized during the Delta- and Omicron-Predominant Periods.
    Stupica D; Collinet-Adler S; Kejžar N; Poljak M; Štamol T
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
    Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
    JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.
    Vo AD; La J; Wu JT; Strymish JM; Ronan M; Brophy M; Do NV; Branch-Elliman W; Fillmore NR; Monach PA
    JAMA Netw Open; 2022 Oct; 5(10):e2240037. PubMed ID: 36264571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study.
    Wang J; Dong H; Zhao J; Li T; Wang M; Zhou C; Mu H
    Front Microbiol; 2023; 14():1096022. PubMed ID: 37065120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical features of children with coronavirus disease 2019 Delta variant infection after vaccination with inactivated SARS-CoV-2 vaccine].
    Su H; Zhang X; Duan FY; Ren XQ; Yan YB; Ding Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):742-747. PubMed ID: 35894187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
    Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
    Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Casado I; Navascués A; Burgui C; Ezpeleta C; Castilla J; Guevara M; ;
    Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022.
    Klaassen F; Chitwood MH; Cohen T; Pitzer VE; Russi M; Swartwood NA; Salomon JA; Menzies NA
    medRxiv; 2022 Nov; ():. PubMed ID: 36451882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021.
    Taylor CA; Patel K; Pham H; Whitaker M; Anglin O; Kambhampati AK; Milucky J; Chai SJ; Kirley PD; Alden NB; Armistead I; Meek J; Yousey-Hindes K; Anderson EJ; Openo KP; Teno K; Weigel A; Monroe ML; Ryan PA; Henderson J; Nunez VT; Bye E; Lynfield R; Poblete M; Smelser C; Barney GR; Spina NL; Bennett NM; Popham K; Billing LM; Shiltz E; Abdullah N; Sutton M; Schaffner W; Talbot HK; Ortega J; Price A; Garg S; Havers FP;
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(43):1513-1519. PubMed ID: 34710076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
    Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ;
    Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.